

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 425

BOSTON SCIENTIFIC CORP

Form 425

February 06, 2006

Filed by Boston Scientific Corporation  
Pursuant to Rule 425 under the Securities Act of 1933  
and deemed filed pursuant to Rule 14a-12  
under the Securities Exchange Act of 1934

Subject Company: Guidant Corporation  
Commission File No.: 001-13388

The following presentation material was distributed to Guidant employees on February 6, 2006.

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---



[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---



[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---



[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

[Link to searchable text of slide shown above](#)

---

**Searchable text section of graphics shown above**

---



[LOGO]

[GRAPHIC]

**Guidant**  
**All-Employee Meetings**

**February 1, 2006**

---

**Transition Principles**

[LOGO]

Rapid close

Open communication

Minimize disruption

Rapid cycles of discussions and decisions

Engage employees

Focus on value creation drivers

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**Boston Scientific's mission is to improve the quality of patient care and increase health care productivity**

**Boston Scientific's Mission Statement**

[GRAPHIC]

**Boston Scientific's mission is to improve the quality of patient care and the productivity of health care delivery through the development and advocacy of less-invasive medical devices and procedures.**

**This is accomplished through the continuing refinement of existing products and procedures and the investigation and development of new technologies that can reduce risk, trauma, cost, procedure time and the need for aftercare.**

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**Boston Scientific has evolved from early pioneer to industry leader**

**Global Leadership in Interventional Medicine**

[CHART]

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**Boston Scientific is a global, multi-billion dollar company focused on less-invasive medical devices and procedures**

**Boston Scientific Corporation Profile**

[GRAPHIC]

**General Facts:**

Founded in 1979 with 38 employees, \$2 million in sales. Now Fortune 500 company

World's largest medical device company dedicated to less-invasive therapies

Portfolio of 15,000 products, many with market leading positions

The TAXUS® drug eluting stent has been the most successfully launched product in the history of the industry

Corporate HQ: Natick, MA

Regional HQs: Singapore, Paris, Tokyo

Website: [www.bostonscientific.com](http://www.bostonscientific.com)

**Product Innovation:**

9,000+ Patents issued

\$569 Million invested in R&D ( '04)

\$1.2 Billion in 22 Investments ( '04)

**Financials:**

\$5.6 Billion Revenue ( 04)

27.5% CAGR\* ( 01- 04)

\$1.4 Billion Net Income ( 04)

NYSE: BSX

**Demographics:**

19,500+ Employees

Direct marketing & sales in more than 40 countries

16 Primary manufacturing locations in U.S., Ireland & Costa Rica

---

\*

Compound Annual Growth Rate

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**A strong management team is leading Boston Scientific through its next phase of growth**

[GRAPHIC] **James R. Tobin**  
President and Chief Executive Officer

[GRAPHIC] **Paul LaViolette**  
Chief Operating Officer

**Executive Committee**

Lawrence C. Best Executive Vice President for Finance and Administration, and Chief Financial Officer

Brian R. Burns Senior Vice President, Quality

Fred A. Colen Executive Vice President & Chief Technology Officer

Paul Donovan Senior Vice President, Corporate Communications

Jim Gilbert Senior Vice President

Jeff H. Goodman Senior Vice President, and President of International

Stephen F. Moreci Senior Vice President & Group President, Endosurgery

Ken Pucel Senior Vice President, Operations

Lucia L. Quinn Senior Vice President, Human Resources

Dr. Mary E. Russell, MD, FACC Senior Vice President, Clinical and Regulatory, and Chief Medical Officer

Paul W. Sandman Executive Vice President, Secretary and General Counsel

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**



**Boston Scientific is organized into three major groups and eleven distinct businesses**

[LOGO]



**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**Strategic Priorities**

**A. Accelerate profitable base-business growth.**

**B. Invest to expand DES market and fortify global leadership**

**C. Deliver on game changer products & markets**

**D. Build new scale beyond catheter/stent platforms: CRM and others.**

**E. Continuously improve an efficient, effective organization**

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**Boston Scientific products help treat a broad range of medical conditions throughout the body**

NEUROMODULATION		NEUROVASCULAR
PERIPHERAL VASCULAR		ELECTROPHYSIOLOGY
VASCULAR SURGERY	[GRAPHIC]	CARDIOVASCULAR
ONCOLOGY		GYNECOLOGY
ENDOSCOPY		UROLOGY

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**Over 25 years of Innovation has led to a broad portfolio of more than 15,000 products**

**Sampling of Boston Scientific's Product Portfolio**

[GRAPHIC] <b>Detachable Coils</b>	[GRAPHIC] <b>Balloons</b>	[GRAPHIC] <b>Grafts</b>	[GRAPHIC] <b>Enteral Feeding</b>	[GRAPHIC] <b>Ablation</b>
[GRAPHIC] <b>Cardiac Mapping</b>	[GRAPHIC] <b>Embolics</b>	[GRAPHIC] <b>Stents</b>	[GRAPHIC] <b>Stone Retrieval</b>	[GRAPHIC] <b>Embolic Protection</b>
[GRAPHIC] <b>Biopsy Systems</b>	[GRAPHIC] <b>Peripheral Dilatation</b>	[GRAPHIC] <b>Ureteral Stents</b>	[GRAPHIC] <b>Catheters / Guidewires</b>	[GRAPHIC] <b>Neuro-stimulation</b>

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**We Achieve Global Leadership in our Key Markets**

**Interventional Cardiology**

[CHART]

90%+ of sales from market leading products

Represents 73% of BSC total business

**Endosurgery**

*(Endoscopy, Oncology, Urology, Gynecology)*

[CHART]

75% of sales from market leading products

Represents 19% of BSC total business

**Q4 2004; Source: company results, analyst reports, MRG reporting**

**Includes vascular sealing and embolic protection**

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**The Neuromodulation group was formed in 2004 and represents an exciting growth opportunity for BSC**

**Neuromodulation Group**

Revenue by Business

[CHART]

2004	\$	46 Million
2005 est.	\$	146 Million

**Medical Conditions**

Chronic Pain

Neurological Disorders

Hearing Loss/Deafness

Migraine Headaches

**Solutions**

Neurostimulation

Cochlear Implants

Spinal Cord Stimulators

Microstimulators

[GRAPHIC]

**Precision® Spinal Cord Stimulator**

[LOGO] The Neuromodulation Group was formed through the acquisition of Advanced Bionics in 2004.

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

[LOGO]

[GRAPHIC]

## **Accelerate profitable base-business growth**

---



**Accelerate profitable base-business growth. Growth in existing markets**

[GRAPHIC]  
**Pain Management**

[GRAPHIC]  
**Auditory**

[GRAPHIC]  
**Drug-Eluting Stents**

[GRAPHIC]  
**Neurovascular Stents**

[GRAPHIC]  
**Endoscopy**

[GRAPHIC]  
**Women's Health**

[GRAPHIC]  
**Endourology**

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

[LOGO]

[GRAPHIC]

## **Invest to expand DES market and fortify global leadership**

---

**DES Pipeline**

[GRAPHIC]

Apex Balloon Catheter

Radical Advances

[GRAPHIC]

TAXUS® Barracuda Stent

New stent material- thin struts w/o compromise

Apex -based delivery

[GRAPHIC]

Long-term DES GLP studies underway

FIM Planned for '06

[GRAPHIC]

TAXUS® Petal™ Bifurcation Stent

Barracuda & Apex Technology

Design optimization & pre-clinical studies underway

[GRAPHIC]

Not Available for Sale in the U.S.

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

[LOGO]

[GRAPHIC]

**Deliver on game changer products & markets**

---

## Robust Product Pipeline

### Product Priorities that may shape our future

[GRAPHIC]  
**Cardiac Rhythm  
Management (CRM)  
Cameron Health  
Cardioverter Defibrillator(1)**

[GRAPHIC]  
**Carotid Stenting and  
Embolic Protection  
EndoTex NexStent (1)  
Wallstent® (2)**

[GRAPHIC]  
**Endovascular Aortic  
Repair (EVAR)  
TriVascularAAA  
Stent Graft (1)**

[GRAPHIC]  
**Next-Generation  
Drug-Eluting Stents  
TAXUS® Liberté (2)**

[GRAPHIC]  
**Single-Use  
Endoscope  
Endovations (1)**

[GRAPHIC]  
**Bifurcated Stents  
Petal Stent (1)**

[GRAPHIC]  
**Pain  
Management  
Precision Spinal Cord  
Stimulation System**

[GRAPHIC]  
**Pain  
Management  
ion Microstimulator (1)**

**Endoscopy Suite**

---

(1) CAUTION: Investigational device. Limited by Federal law to investigational use.

(2) Not available for sale in the United States.

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

[LOGO]

[GRAPHIC]

**Build new scale beyond catheter/stent platforms: CRM and others.**

---

**CRM Market**  
Why we like it!

[CHART]

	Forecasted 06 08 CAGR
<b>Total</b>	<b>12%</b>
<b>ICDs</b>	<b>10%</b>
<b>CRT-Ds</b>	<b>23%</b>
<b>Pacemakers</b>	<b>3%</b>

*Source: Wall Street Research.*

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**



**Guidant Acquisition**

**Consistent with BSC Strategy**

**Long-term interest in CRM**

**DES Alternative**

**Diversification and Growth**

[GRAPHIC]

[GRAPHIC]

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**Achieving Enhanced Diversification and Higher Growth**

**Boston Scientific Sales Breakdown**

[CHART]

**Combined Pro Forma Sales Breakdown**

[CHART]

**Preeminent pure play in medical devices**

*Source: BSC Management estimates. Figures shown assume 2006 full year of combined operation, adjusted for planned Guidant asset divestitures.*

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**Key Value Drivers**

**CRM Market Position Recovery Goals**

[GRAPHIC]

[CHART]

*Source: Company estimates.*

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**Key Value Drivers**

**Growth Through DES Platform Diversification**

[GRAPHIC]

[GRAPHIC]

**TAXUS position**  
**Pipeline**  
**Primary program**

**Immediate access**  
**Differentiated platforms**  
**Olimus alternative**

**TECHNOLOGY PORTFOLIO**

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

## Creating a Global Leader in Cardiovascular Devices

### 2006 Est. Cardiovascular Device Sales

[CHART]

*Note: BSC-Guidant based on Wall Street Case and Company estimates, reflecting full year of combined operation adjusted for planned Guidant asset divestitures. All others based on Wall Street Research.*

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

[LOGO]

[GRAPHIC]

**Continuously improve an efficient and effective organization**

---

**Current Initiatives that drive continuous improvements**

Project Horizon

[GRAPHIC]

E-Manufacturing

[GRAPHIC]

STRIVE

[GRAPHIC]

Japan Restructuring

[GRAPHIC]

Lean Product Development Proc

[GRAPHIC]

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

**Boston Scientific Invests in the Communities  
Where We Work and Live**

[GRAPHIC]

As Boston Scientific has grown, so has our commitment to giving back to the communities where we work and live

Through the Boston Scientific Foundation, we support organizations and causes that support individuals and communities by promoting improvements in two critical areas – health and education

Since its inception in 2002, the Foundation has donated approximately \$4 million in grants to more than 150 charitable organizations

Annually, Boston Scientific contributes more than \$25 million towards research, education and local communities

We continue to organize and participate in numerous volunteer programs at Boston Scientific sites worldwide

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**



**Where else would we rather be?**

Growth

[CHART]

Guidant

[CHART]

Size and Shape

[CHART]

Future Technologies

[GRAPHIC]

**Confidential information of Boston Scientific Corporation. Do not copy or distribute.**

[LOGO]

[GRAPHIC]

**Thank you.**

---